Private Equity
SoftBank Group Corp has raised $108 billion for its second Vision Fund that targets tech firms, reported Reuters. The investors include Microsoft and Apple. SoftBank plans to invest $38 billion in the fund.
1 min read · 26 July 2019
2 min read · 26 July 2019
3 min read · 26 July 2019
Conexus Credit Union has launched a $30 million venture capital fund intended to invest in Saskatchewan's startup ecosystem. Conexus Venture Capital Fund has so far raised $22.5 million, of which $15 million came from Conexus, a Regina-based credit union, and $7.5 million from external investors. Managed by Conexus, the fund will invest in Saskatchewan-based companies in partnership with other venture capital firms and investors. Opportunities will be sourced in part through Cultivator, a Conexus-sponsored incubator located in Regina. The fund is led by Conexus Venture Capital Fund Manager Sean O’Connor. It has already finalized two deals and is expected to execute on others in the months ahead.
4 min read · 25 July 2019
OSF Ventures has raised $75 million for its second venture fund. The fund will invest in new technology, devices and services that offer improved and more cost efficient health care.
3 min read · 25 July 2019
Salt Lake City-based Health Catalyst, a provider of data and analytics technology and services to healthcare organizations, has raised $182 million for its IPO after pricing its 7 million shares at $26 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "HCAT." Goldman Sachs, J.P. Morgan and William Blair are the lead underwriters. Health Catalyst's pre-IPO backers included OrbiMed, Sequoia Capital, Norwest Venture Partners, Sands Capital Ventures, UPMC Enterprises and Kaiser Permanente Ventures.
3 min read · 25 July 2019
Friendswood, Texas-based Castle Biosciences Inc, a dermatological cancer company, has raised $64 million for its IPO after pricing its 4 million shares at $16 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "CSTL." SVB Leerink and Baird are the lead underwriters. Castle Biosciences' pre-IPO backers included Industry Ventures, HealthQuest Capital and Mountain Group Partners.
2 min read · 25 July 2019
Silicon Valley and Tel Aviv-based BGV, an early-stage venture firm, has closed its opportunity fund at $70 million. BGV invests in enterprise 4.0 opportunities in global markets.
3 min read · 25 July 2019
2 min read · 24 July 2019
VMG Partners has closed a new fund at $250 million. Named VMG Catalyst, the fund will focus on early stage tech-enabled consumer products, services, experiences and marketplaces as well as the infrastructure and technology stack that enable these businesses.
2 min read · 24 July 2019
